Hikma Reaches Licensing Agreement With Celltrion For Third Biosimilar Product In The Middle East And North Africa
London, 19 December 2017 – Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody’s / BB+ S&P, both stable) announces that it has reached a licensing agreement with South Korea-based Celltrion, Inc. and Celltrion Healthcare, Inc (Celltrion) for the first biosimilar monoclonal Antibody (mAb) in oncology to be granted European marketing authorisation, Truxima™ (rituximab). Hikma now has exclusive agreements with Celltrion for three biosimilar products - Truxima™ (rituximab), Remsima® (infliximab) and Herzuma® (trastuzumab) – in all its MENA markets.
Truxima™ is mAb biosimilar to Roche’s MabThera® (rituximab), which is used to treat patients with non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis.
Under the terms of the agreement, Hikma has the exclusive rights to distribute and market Truxima™ (rituximab) in all of its MENA markets, leveraging Hikma’s strong local presence, biosimilar expertise, sales and marketing capabilities and regulatory expertise.
Mazen Darwazah, Vice Chairman and CEO of MENA and Emerging Markets said, “We are pleased to be adding Truxima™ to our biosimilar and oncology portfolio, building on the success of our partnership with Celltrion in the MENA region. Global partnerships are an integral part of our strategy to enhance our portfolio in key therapeutic areas and increase patients’ access to high-quality, affordable medicines.”